Himanshu¹*, Sameeksha¹ and Mukesh Kumar²

¹Bachelor of Pharmacy, NGI College of Pharmacy, NGI Campus, Near Sardar Vallabh Bhai Patel Agriculture University, Modipuram, Meerut, Uttar Pradesh, India
²Department of Pharmaceutics, Kharvel Subharti College of Pharmacy, Swami Vivekanand Subharti University, Subhartipuram, Delhi-Haridwar Bypass Road, Meerut, Uttar Pradesh, India

*Corresponding Author: Himanshu, Bachelor of Pharmacy, NGI College of Pharmacy, NGI Campus, Near Sardar Vallabh Bhai Patel Agriculture University, Modipuram, Meerut, Uttar Pradesh, India.

Received: March 18, 2022; Published: March 29, 2022

Abstract

Pharmaceutical liquid dosage forms are the liquid solutions that can be ingested, applied topically, or administered intravenously. These dosage forms are made up of a mixture of active medicines and excipients that produce a quick beginning of action after ingestion and provide the best therapeutic response in a given population. Pharmaceutical liquid dose forms are helpful and efficient for pediatric, elderly, and comatose patients who have difficulty swallowing solid dosage forms such as pills, capsules, and other medications. As a result, pharmaceutical liquid dosage forms are extremely important in the treatment and management of a wide range of disorders around the global. This article covers a wide range of topics related to pharmaceutical liquid dosage forms, including classification, benefits and drawbacks, excipients utilised in pharmaceutical liquid dosage forms, solubility enhancement techniques, and some of the instruments used to improve mixing.

Keywords: Solubility; Bioavailability; Excipients; Lipophilicity

References

1. Peter ASA., et al. “A Study on the Different Methods of Preparation of Lutein from Supercritical Fluid Processed Lutein Esters”. Journal of Nutrition and Food Sciences 2 (2012): 154.
2. Allen L. “Art, Science, and Technology of Pharmaceutical Compounding, (The) 5e”. Washington, DC: American Pharmacists Association (2016).
3. Marriott J., et al. “Pharmaceutical compounding and dispensing”. 2^nd Pharmaceutical Press (2010).
4. White AR. “The Success of Solanezumab Should Drive Renewed Efforts to Develop Small Molecule Anti-Amyloid Agents for Alzheimer’s disease Therapy”. Drug Designing 4 (2015): e128.
5. Gomase VS and Kale KV. “Information of Surface Accessibility of the Peptide Fragments of Coat Protein from Alfalfa mosaic virus (AMV) at the Physicochemical and Immunochemical Levels”. Drug Designing 4 (2015): 119.
6. Chow SC. “On Assessment of Analytical Similarity in Biosimilar Studies”. Drug Designing 3 (2014): e124.
7. Lopes CM. “Therapeutics Delivery: Innovations Technology Approaches”. Lopes, Drug Designing 3 (2014): e123.
8. Chow SC and Pong A. “Statistical Designs for Pharmaceutical/Clinical Development”. Drug Designing 3 (2014): 112.
9. Anil Vaidya. “Drug Designing and Development: Emerging Role of Health Technology Assessment”. Drug Designing 3 (2014): 111.
10. Coelho M. “Fate of Vitamins in Premixes and Feeds: Vitamin Stability”. Feed Management 10 (1991): 24.
11. Manzur Ul and Haque H. “Assay of Vitamins in Pharmaceutical Preparations”. 7.10 (1972): 213-226.
12. Howard CA., et al. “Pharmaceutical Dosage Forms and Drug Delivery Systems”. 7Edn (2000): 38-64.
13. Kumar P and Bose PP. “Targeted Delivery of Paromomycin to Leishmania Infected Macrophage by Hemoglobin Tagged Nanocarrier”. Journal of Applied Pharmaceutical Science 8 (2015): 212.
14. Nelson DH and Samuels LT. “A Method for Determination of 17-Hydroxycorticosteroids in Blood: 17-Hydroxycorticosterone in the Peripheral Circulation”. The Journal of Clinical Endocrinology and Metabolism 12 (1952): 519.
15. Glenn EM and Nelson DH. “Chemical Method for the Determination of 17-Hydroxycorticosteroids and 17-Ketosteroids in Urine Following Hydrolysis With β-Glucuronidase”. The Journal of Clinical Endocrinology and Metabolism 13 (1953): 911.
16. Nelson DH., et al. “Blood Levels of 17-Hydroxycorticosteroids Following the Administration of Adrenal Steroids and Their Relation to Levels of Circulating Leukocytes”. Journal of Clinical Investigation 31 (1952): 843.
17. Tan E., et al. “Dosing information for paediatric patients: are they really ‘therapeutic orphans’?” Medical Journal of Australia 4 (2003): 195-198.
18. Ekinci R and Kadakal C. “Determination of seven water-soluble vitamins in Tarhana, a traditional Turkish cereal food, by High-Performance Liquid Chromatography”. Acta Chromatographica 15 (2005): 289-297.
19. Lee V H L and Robinson I R. “Ocuserts for improved drug delivery and better patient compliance”. Journal of Pharmaceutical Sciences1 (1979): 673.
20. Ancha MJ., et al. “Formulation and evaluation of pediatric azithromycin suspension”. International Journal of Pharma and Bio Sciences 1 (2010): 1-2.
21. Marriott J., et al. “Pharmaceutical compounding and dispensing”. 2^nd Pharmaceutical Press (2010).
22. “Remington: The Science and Practice of Pharmacy”. London: Pharmaceutical Press (2012).
23. “The science of pharmaceutical compounding: non-sterile training”. Montreal: LP3 Network Inc (2018).
24. DJ Burgess., et al. “Assuring quality and performance of sustained and controlled release parenteral”. AAPS PharmSciTech 4 (2002): E7.
25. Carstensen TJ. “Theory of Pharmaceutical systems”. Academic press; NY, (1973): 59.
26. A Liberman., et al. “Gilbent’s Pharmaceutical Dosage forms Dispersed systems”. Marcel Dekker 2 (1996): 285.
27. MJ Akers., et al. Journal of parenteral science and Technology 41 (1987): 88.
28. ES Antal., et al. “Comparative bioavailability of two medroxy progesterone acetate suspensions”. International Journal of Pharmaceutics 54 (1989): 33-39.
29. Agarwal SP and Rajesh K. “Physical Pharmacy”. CBS Publisher, Delhi, India (2007): 177-186.
30. Aulton ME. “Pharmaceutics the science of dosage form design”. Charchil Livingston, London, United Kingdom (1996): 282-299.
31. Javed ., et al. Emulsion (2008).
32. Brazeau GA and Fung HL. “Mechanics of retaining kinase release from isolated rat skeletal muscles damaged by propylene glycol and ethanol”. Journal of Pharmaceutical Sciences 79 (1990): 397.
33. Quay JF and Stucky JF. “Non aqueous cephalosporin suspension for parenteral Administration”. Journal of Pharmaceutical Sciences 11 (1989): 1602-1606.
34. British Pharmacopoeia, London, Appendix XVIC (1993): A191192.
35. Huettenrauch R. “Stabilization of suspension”. DD 209970. Al 840530. (1989).
36. Michael H., et al. “Part 1: “Oral Delivery of Poorly Soluble Drugs Pharmaceutical Manufacturing and Packing Sourcer”. Summer Samedan Ltd, (2003): 03.
37. Brahmankar DM and Jaiswal SB. “Biopharmaceutics and Pharmacokinetics - A treatise”. Vallabh Prakashan, Delhi, India (2002).
38. Serajuddin ATM. “Salt formation to improve drug solubility”. Advanced Drug Delivery Review 59 (2007): 603-616.
39. Seshadri N. “Small Molecule Pharmaceutics - Amgen Inc. Strategies to Impact Solubility and Dissolution Rate during Drug Lead Optimization: Salt Selection and Prodrug Design Approaches”. APR 7 (2004): 108-113.
40. Chawla RC., et al. “Effect of alcohol cosolvents on the aqueous solubility of trichloroethylene”. Proceedings of the 2001 conference on environmental research (2001): 52-66.
41. Ohta, M., et al. “Evaluation of solubility parameter to predict apparent solubility of amorphous and crystalline Cefditoren Pivoxil”. Pharmaceutica Acta Helvetiae 74 (1999): 59-64.
42. Merisko Liversidge E., et al. “Nanosizing: a formulation approach for poorly-water-soluble compounds”. European Journal of Pharmaceutical Science 18 (2003): 113-120.
43. Blagden N., et al. “Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates”. Advanced Drug Delivery Review7 (2007): 617-630.
44. Hu J., et al. “Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs”. Drug Development and Industrial Pharmacy3 (2004): 233-245.
45. Nagarsenker MS and Garad, SD. “Physical characterization and optimization of dissolution parameters of prochlorperazine maleate co-evaporates”. International Journal of Pharmaceutics 160 (1998): 251-255.
46. Jalali MB., et al. “Enhancement of dissolution rate and anti-inflammatory effects of piroxicam using solvent deposition technique”. Drug Development and Industrial Pharmacy 28 (2002): 681-686.
47. Cavallari C., et al. “Improved dissolution behaviour of steam granulated piroxicam”. European Journal of Pharmaceutics and Biopharmaceutics 54 (2002): 65-73.
48. Mitchell SA., et al. “A compaction process to enhance dissolution of poorly water-soluble drugs using hydrxypropyl methylcellulose”. International Journal of Pharmaceutics 250 (2003): 3-11.
49. Spireas S and Bolton M. “Liquisolid Systems and Methods of Preparing Same, U.S. Patent 5,968,550”. (1999).
50. Karmarkar AB., et al. “Liquisolid Tablets: A Novel Approach for Drug Delivery”. International Journal of Health Research1 (2009): 45-53.

Citation

Citation: Himanshu., et al. “A Comprehensive Review on Pharmaceutical Liquid Dosage Form". Acta Scientific Pharmaceutical Sciences 6.4 (2022): 12-24.

Copyright

Copyright: © 2022 Himanshu., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.